AVITA Medical, Inc. (RCEL) stock
RCELNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31Also trades as AVHHL
$16.83+1.06 (+6.72%)
Close on Nov 18, 2026Market cap $520.50MP/E –Yield –
AVITA Medical free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
AVITA Medical's free cash flow for the twelve months ending Jun 30, 2026 was -$24.62M. For fiscal 2025 it was -$32.21M. The highest annual figure on record is -$13.33M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.21M | – |
| FY2024 | Dec 31, 2024 | -$58.07M | – |
| FY2023 | Dec 31, 2023 | -$39.39M | – |
| FY2021 | Jun 30, 2021 | -$26.80M | – |
| FY2020 | Jun 30, 2020 | -$23.34M | – |
| FY2019 | Jun 30, 2019 | -$20.27M | – |
| FY2018 | Jun 30, 2018 | -$13.33M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$3.60M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$10.09M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$4.77M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$6.15M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$10.75M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$10.53M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$9.65M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$10.97M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$15.43M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$22.01M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$11.16M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$9.48M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$9.40M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$9.36M | – |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -$4.07M | – |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -$8.87M | – |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -$5.94M | – |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -$7.92M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$6.04M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$7.63M | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$4.70M | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$4.97M | – |
See a number that looks wrong?